ADAG - Adagene Inc.
3.77
-0.370 -9.814%
Share volume: 135,989
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.18%
PREVIOUS CLOSE
CHG
CHG%
$4.14
-0.37
-0.09%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-7.37%
1 Month
27.36%
3 Months
107.60%
6 Months
89.45%
1 Year
148.03%
2 Year
16.36%
Key data
Stock price
$3.77
DAY RANGE
$3.62 - $4.14
52 WEEK RANGE
$1.30 - $4.58
52 WEEK CHANGE
$148.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
Company detail
CEO: Pei Z. Luo
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.
Recent news